Excessive daytime sleepiness Market

• Advancements in application modalitiesis driving the market growth

Within the excessive daytime sleepiness (EDS) market, a notable trend is the continuous advancement of Application modalities. Emerging therapies, such as novel medications targeting specific neurotransmitters or innovative approaches like neuromodulator techniques, are gaining attention. As researchers delve deeper into understanding the underlying causes of EDS, the development of more effective and targeted Applications is on the rise. This trend reflects a commitment to addressing the complexities of excessive daytime sleepiness with a diverse range of therapeutic options, providing patients with tailored and improved solutions beyond traditional medications. This factor drives the market CAGR.

Additionally, an evolving trend in the excessive daytime sleepiness market involves the integration of wearable technology for monitoring and managing sleep-related conditions. Wearable devices equipped with advanced sensors can track sleep patterns, monitor physiological parameters, and provide real-time data on sleep quality. This trend aligns with the growing demand for patient-centric solutions and facilitates more precise diagnostic measures. The incorporation of wearable technology not only aids in the accurate assessment of daytime sleepiness but also promotes a proactive approach to managing sleep disorders, fostering a trend towards personalized and data-driven healthcare interventions.

In response to the increasing prevalence of excessive daytime sleepiness and the need for accessible healthcare solutions, the market is witnessing a surge in telemedicine and virtual care platforms. Telehealth services allow patients to consult sleep specialists remotely, facilitating convenient access to expert advice and diagnostic evaluations. This trend is particularly relevant in the context of sleep disorders, as it overcomes geographical barriers and enhances patient engagement.

The integration of virtual care platforms in the excessive daytime sleepiness market represents a shift towards more patient-centric and inclusive healthcare delivery, ensuring that individuals can receive timely and comprehensive care regardless of their location. For instance, in February 2023, Pharmanovia announced the expansion of its neurology portfolio via a new licensing agreement with Axsome Therapeutics, Inc. Sunosi (solriamfetol), a first-in-class drug used to increase alertness and reduce EDS in individuals with narcolepsy or obstructive sleep apnoea (OSA), was expected to be marketed exclusively by Pharmanovia in Europe and the Middle East and North Africa (MENA).

Thus, driving the excessive daytime sleepiness market revenue.

The Global Excessive Daytime Sleepiness Market Industry is poised for substantial growth, with projections indicating a market value of 5.98 USD Billion in 2024 and an anticipated increase to 12.0 USD Billion by 2035. This growth trajectory suggests a compound annual growth rate (CAGR) of 6.52% from 2025 to 2035. Such figures reflect the increasing recognition of excessive daytime sleepiness as a critical health issue, prompting investments in research and development of effective treatments and technologies. Stakeholders in the industry are likely to capitalize on this growth by innovating and expanding their offerings to meet the evolving needs of consumers.

Modern lifestyle changes, including increased stress levels and sedentary behavior, are contributing to the rise of excessive daytime sleepiness, thus impacting the Global Excessive Daytime Sleepiness Market Industry. Factors such as long working hours, poor dietary habits, and lack of physical activity are leading to sleep disturbances. As more individuals recognize the link between lifestyle choices and sleep quality, there is a growing demand for interventions aimed at improving sleep hygiene. This trend is likely to drive market growth, as consumers seek effective solutions to combat the adverse effects of their lifestyles on sleep.

The aging demographic is a significant factor driving the Global Excessive Daytime Sleepiness Market Industry. As the global population ages, the prevalence of sleep disorders tends to increase, leading to higher instances of excessive daytime sleepiness. Older adults often experience changes in sleep patterns and are more susceptible to conditions that disrupt sleep. This demographic shift necessitates tailored solutions to address their unique sleep needs. With the market expected to grow substantially, the aging population presents both challenges and opportunities for stakeholders in the sleep health sector.

There is a growing recognition of the importance of sleep health among the global population, which serves as a catalyst for the Global Excessive Daytime Sleepiness Market Industry. Public health campaigns and educational initiatives are raising awareness about the detrimental effects of sleep deprivation and excessive daytime sleepiness. This heightened awareness is leading to increased demand for diagnostic tools and treatment options. As individuals become more informed about the consequences of poor sleep, they are more likely to seek medical advice and interventions, thereby propelling market growth. The anticipated CAGR of 6.52% from 2025 to 2035 underscores the potential for sustained expansion in this sector.

The increasing incidence of sleep disorders globally is a primary driver of the Global Excessive Daytime Sleepiness Market Industry. Conditions such as obstructive sleep apnea and narcolepsy are becoming more prevalent, affecting millions worldwide. For instance, it is estimated that around 22 million Americans suffer from sleep apnea alone. This growing awareness and diagnosis of sleep-related issues contribute to the market's expansion, as more individuals seek treatment options. The Global Excessive Daytime Sleepiness Market is projected to reach 5.98 USD Billion in 2024, reflecting the urgent need for effective solutions to combat excessive daytime sleepiness.

Innovations in sleep technology are significantly influencing the Global Excessive Daytime Sleepiness Market Industry. The development of wearable devices and mobile applications that monitor sleep patterns and provide personalized recommendations is gaining traction. These advancements not only enhance the quality of sleep but also empower users to manage their sleep health proactively. For example, smartwatches equipped with sleep tracking features are becoming increasingly popular. As these technologies evolve, they are likely to drive market growth, with projections indicating a market value of 12.0 USD Billion by 2035, highlighting the potential for continued innovation in sleep management.

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American excessive daytime sleepiness market area will dominate this market, owing to an increased awareness and proactive initiatives in North America regarding the importance of sleep health and the consequences of untreated sleep disorders lead to higher rates of diagnosis and intervention. In addition, the growing number of establishing health clubs and fitness facilities will boost market growth in this region.

Further, the major countries studied in the market reportare The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure2: EXCESSIVE DAYTIME SLEEPINESS MARKET SHARE BY REGION 2022 (USD Billion)

Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

Europeexcessive daytime sleepiness market accounts for the second-largest market share due to the excessive daytime sleepiness, influenced by factors such as lifestyle changes and work-related stress. Further, the Germanexcessive daytime sleepiness market held the largest market share and the UK excessive daytime sleepiness market was the fastest growing market in the European region

The Asia-Pacific Excessive daytime sleepiness Market is expected to grow at the fastest CAGR from 2023 to 2032. This is due toimproving healthcare infrastructure and the growing awareness of sleep-related issues contributes to an enhanced diagnosis and Application landscape.Moreover, China’sexcessive daytime sleepiness market held the largest market share, and the Indianexcessive daytime sleepiness market was the fastest growing market in the Asia-Pacific region.

Leading market players are investing heavily in research and development in order to expand their product lines, which will help the excessive daytime sleepiness market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, excessive daytime sleepiness industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the excessive Daytime Sleepiness industry to benefit clients and increase the market sector. In recent years, the excessive daytime sleepiness industry has offered some of the most significant advantages. Major players in the excessive daytime sleepiness market, including Teva Pharmaceutical Industries Ltd.,GE Healthcare ,Jazz Pharmaceuticals,CompumedicsFisher & Paykel Healthcare,BIOPROJET,BMC Medical Co. Ltd.,Avadel Pharmaceuticals plc ,Cadwell Laboratories Inc. Ltd ,GlaxoSmithKline plc ,Braebon Medical Corporation ,Pfizer and others, are attempting to increase market demand by investing in research and development operations.

Harmony Biosciences Holdings, Inc. was founded in 2017 and is headquartered in Plymouth Meeting, Pennsylvania, USA. The company is dedicated to addressing unmet needs in sleep and CNS disorders, with a focus on bringing transformative Applications to patients.Harmony Biosciences is known for its emphasis on narcolepsy, a sleep disorder characterized by excessive daytime sleepiness. The company has developed and commercialized medications specifically designed to address symptoms associated with narcolepsy. Harmony Biosciences Holdings, Inc. initiated a Phase 3 trial evaluating the efficacy and safety of pitolisant in adult patients with idiopathic hypersomnia (IH), known as the INTUNE study.

NLS Pharma Ltd. is a biopharmaceutical company dedicated to advancing innovative Applications for central nervous system disorders, with a particular focus on narcolepsy. Privately held, the company is committed to addressing unmet medical needs in the field of neurological and psychiatric conditions through research, development, and the advancement of novel therapies. With a pipeline of drug candidates, NLS Pharma aims to contribute to improved outcomes for patients experiencing symptoms such as excessive daytime sleepiness and cataplexy.

NLS pharma Ltd. reported that the European Medicines Agency (EMA) Committee for Orphan Medical Products (COMP) has issued a positive opinion to grant Orphan Drug Designation (ODD) for Mazindol ER (Quilience) for the Application of idiopathic hypersomnia (IH).